Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
New Drug Application (NDA): If clinical trials demonstrate that the drug is safe and effective, the sponsor submits an NDA to the FDA, which includes all data from the trials, labeling information, and manufacturing details
doi: 10.3389/fendo.2019.00155 Received 04 December 2018 Accepted 21 February 2019 Published 12 April 2019 Volume 10 - 2019 Edited by Milka Vrecl, University of Ljubljana, Slovenia Reviewed by Jean Albert Boutin, Servier, France
Research use only SLU-PP-332 research peptide SLU-PP-332 is a synthetic small-molecule pan agonist of the estrogen-related receptors ERRalpha, ERRbeta, and ERRgamma, with the highest reported potency at ERRalpha
Santos et al
Beware of Counterfeits: How to Identify the Original With high demand, counterfeit products have emerged
US$ 21.24
US$ 20.12
US$ 27.56
US$ 26.35
US$ 29.29
US$ 22.89
US$ 22.41
